- Nova Mentis Life Science (NOVA) has announced the appointment of Derek Ivany to the position of Executive Chairman
- Ivany has a rich history of working with publicly traded companies and helping generate significant shareholder value
- Nova Mentis is a Canadian-based biotechnology company
- Nova Mentis Life Science Corp. (NOVA) opened trading at C$0.09 per share
Nova Mentis Life Science (NOVA) has announced the appointment of Derek Ivany to the position of Executive Chairman.
In this new role, Ivany’s mandate will include specific focus on corporate development outreach, mergers and acquisitions, capital markets support and other strategic value enhancement initiatives.
Ivany has been a long-term shareholder and supporter of NOVA. This is by virtue of his previous position as Founder, President and Director of Pilz Bioscience Corp. He started Pilz Bioscience with NOVA’s Dr. Marvin S. Hausman that was subsequently acquired by NOVA in November 2020.
Ivany has a rich history of working with publicly traded companies and helping generate significant shareholder value. He has worked in a variety of diverse industry segments and with many international groups and has established a network of high-profile contacts across such sectors.
Will Rascan, President and CEO of NOVA, commented on the appointment.
“Derek’s expertise and leadership will be invaluable as we initiate our Health Canada clinical trial. As we advance our clinical pipeline, it is important that we continue to increase our profile with both retail and institutional biotechnology investors within the capital markets. We look forward to working with Ivany as he spearheads this initiative.”
The company also announced that Steve Feldman has resigned from NOVA’s Board of Directors.
Nova Mentis is a Canadian-based biotechnology company. The company develops diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders.
Nova Mentis Life Science Corp. (NOVA) opened trading at C$0.09 per share.